No abstract

255 Neurocirugía 2011; 22: 255-260 Resumen Introducción. La histiocitosis sinusal con linfadenopatías masivas (HSLM), también conocida como enfermedad de Rosai-Dorfman (ERD), es una histiocitosis idiopática que suele afectar a los ganglios linfáticos. Ocasionalmente puede afectar al SNC, siendo excepcional la afectación intracraneal sin lesiones ganglionares. En ausencia de signos radiológicos típicos, los pacientes afectos son generalmente intervenidos bajo la sospecha de un meningioma, obteniéndose el diagnóstico histológico tras el procedimiento quirúrgico. Es una entidad clínico-patológica poco conocida, existiendo controversia sobre su etiopatogenia, curso clínico y manejo terapéutico.Caso clínico. Presentamos el caso de un paciente de 40 años que debutó con dos crisis tónico-clónicas generalizadas y en la RM cerebral se objetivó una lesión extraaxial parieto-occipital izquierda con extensión hacia la fosa posterior, sin presentar lesiones a otros niveles. Se realizó una resección parcial de la lesión y la anatomía patológica fue informada como enfermedad de Rosai-Dorfman.Conclusiones. A pesar de su baja frecuencia, deberíamos incluir a la ERD en el diagnóstico diferencial de las lesiones nodulares durales, frente a otras más frecuentes como son los meningiomas. Debido a la inespecificidad de las pruebas complementarias su diagnóstico es eminentemente histológico. Se precisan más estudios para definir la mejor opción terapéutica.PALABRAS CLAVE. Enfermedad de Rosai-Dorfman. Histiocitosis sinusal con linfadenopatías masivas, Emperipolesis. Isolated intracranial Rosai-Dorfman disease: A case report and literature review SummaryIntroduction. Sinus histiocytosis with massive lymphadenopathy, also known as Rosai-Dorfman disease (RDD) is an idiopathic histiocytosis that usually affects the lymph nodes. Occasionally it may affect the CNS, being exceptional intracranial involvement without lymph node lesions. In the absence of typical radiological signs, affected patients are generally operated under the suspicion of a meningioma. The histological diagnosis is obtained after the surgical procedure. It is a clinicopathological entity not well known, controversy exists about its pathogenesis, clinical course and therapeutic management.Case report. We report the case of a 40-year-old male presented two generalized tonic-clonic seizures and brain MRI showed a left parieto-occipital extra-axial lesion extending into the posterior fossa, without presenting lesions at other levels. A partial resection of the lesion was performed and the histological findings were reported as Rosai-Dorfman disease.Conclusions. Despite its low frequency, the ERD should be included in the differential diagnosis of dural-based masses, compared to more common, such as meningiomas. Due to lack of specificity of additional studies its diagnosis is fundamentally histologic. More research is needed to define the best therapeutic option.KEY WORDS. Rosai-Dorfman disease. Sinus histiocytosis with massive lymphadenopathy. Emperipolesis. Introducció...

No abstract

e14033 Background: IDH-mutant tumors are a distinct disease entity accounting for one third of gliomas with a more favourable prognosis despite still harboring high morbidity and mortality rates. Most IDH mutations (muts) in gliomas group at R132/R172 hotspots in IDH1/IDH2, respectively. Our aim was to study IDH non-canonical muts and IDH co-mutations (co-muts) since the evidence is still limited. Methods: Prospective study of patients (pts) with gliomas at 4 third-level hospitals in Spain (Hospital Clinico Universitario San Carlos, Hospital Universitario La Paz, Hospital Universitario de Canarias, Hospital Universitario Nuestra Señora de la Candelaria). High throughput next generation sequencing (NGS) using a customized gene panel ((Illumina, Inc) including IDH1 and IDH2 was used in FFPE and/or fresh tumor samples, and run in an Illumina MiSeq instrument (Illumina, Inc). Only pathogenic mutations were considered as valid. Clonal IDH (cIDH) muts were defined as those with a MAF ≥ 1% and subclonal IDH (scIDH) muts as those with a MAF < 1%. Results: Between February 2017 and February 2021, 49 glioma pts enrolled and sequenced for IDH1/IDH2 tumor muts. Median age 51 (Min-max: 20-78). WHO 5th Ed (n = 42): IDH-MUT astrocytoma (n = 14), IDH-MUT oligodendroglioma (n = 7), IDH-WT glioblastoma (n = 21). 37/49 pts (75.5%) presented cIDH and/or scIDH muts, of which 21 pts (43%) harbored cIDH muts in IDH1 (R132H (n = 17), R132C (n = 1), R132G (n = 1), R100Q (n = 1), G161R (n = 1)) and in IDH2 (R140W (n = 1), R140Q (n = 1)). In 17/21 pts (81%) cIDH-mut MAF ≥ 10%. Of 21 cIDH-mutant pts, there were IDH co-muts in 11 pts (52%). Of these 11 pts, IDH co-muts were scIDH in 91%: #2 (IDH1 R100Q/G161R), #3 (IDH1 R132H/R119Q/G161R), #4 (IDH1 R132H/R132C; IDH2 R172G/R140Q), #11 (IDH1 R132H/R132C), #21 (IDH1 R132H/G161R; IDH2 R140Q), #23 (IDH1 R132H/R132C), #31 (IDH1 R132H/G161R; IDH2 R140Q/P162L), #32 (IDH1 R132H/R100Q), #33 (IDH1 R132H/R100Afs*29/I130V), #37 (IDH1 R132H; IDH2 R159H), #40 (IDH1 R132H; IDH2 R172G). Median overall survival (OS) longer in cIDH-mut vs IDH-wt (159 vs 16 months, P = 0.000). No difference in OS in: cIDH vs cIDH + scIDH (NR vs 67 m, P = 0.437), in scIDH vs cIDH (79 vs 159 m, P = 0.111), and scIDH vs IDH-wt (79 vs 12 m, P = 0.229). Conclusions: Subclonal (defined as MAF < 1%) canonical and non-canonical IDH-mutations and co-mutations occur frequently in gliomas. This may have implications for the design of future clinical trials and in the development of IDH inhibitors including the anticipation of potential resistance mechanisms.

No abstract